The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Pimozide for tics in Tourette's syndrome
Open accessAbstract
BACKGROUND: Neuroleptic drugs with potent D-2 receptor blocking properties have been the traditional treatment for tics caused by Tourette Syndrome. Pimozide is the most studied of these. Use of these medications is declining because of concerns about side effects, and new atypical neuroleptics are now available. The true benefit and risks associated with pimozide compared to other drugs is not known. OBJECTIVES: To evaluate the efficacy and harms of pimozide in comparison to placebo or other medications in the treatment of tics in Tourette Syndrome. SEARCH STRATEGY: We cross-referenced pimozide and its proprietary names with Tourette Syndrome and its derivations, as MeSH headings and as text words, and searched the Cochrane Movement Disorders Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 4), MEDLINE (1950-April 2007), and EMBASE (1980-April 2007). Reference lists of relevant articles were reviewed for additional trials. SELECTION CRITERIA: All randomized, controlled, double blind studies comparing pimozide to placebo or other medications for the treatment of tics in Tourette Syndrome were considered for inclusion in this review. Both parallel group and crossover studies of children or adults, at any dose and for any duration, were included. DATA COLLECTION AND ANALYSIS: Data was abstracted independently by two authors onto standardized forms and disagreements were resolved by discussion. MAIN RESULTS: Six randomized controlled trials were included (total 162 participants, age range 7 to 53 years). Pimozide was compared with: placebo and haloperidol (two trials), placebo (one trial), haloperidol (one trial), and risperidone (two trials). Methodological quality was rated 'fair' for all studies. Studies used different outcome measurement scales for assessing tic severity and adverse effects. Significant clinical heterogeneity made meta-analysis inappropriate. Pimozide was superior to placebo in three studies, though it caused more side effects than placebo in one of these. Pimozide was inferior to haloperidol in one of three studies (the other two showed no significant difference between the drugs), which also showed significantly fewer side effects associated with pimozide. No significant differences between pimozide and risperidone were detected. AUTHORS' CONCLUSIONS: Pimozide is an effective treatment for tics in Tourette Syndrome, though the number of trials comparing its effect to placebo and other drugs is limited. Trials of longer duration (minimum six months) are needed to investigate the longer-term effects of pimozide compared to atypical neuroleptics. Future trials should use the Yale Global Tic Severity Scale to assess the main outcome measure, and quantify adverse events with the Extrapyramidal Symptoms Rating Scale.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity
LECKMAN, J. F., RIDDLE, M. A., HARDIN, M. T., ORT, S. I., SWARTZ, K. L., STEVENSON, J., & COHEN, D. J. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198907000-00015 · Cited by 2,146
Current methods of the U.S. Preventive Services Task Force
Harris, R. P., Helfand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00261-6 · Cited by 1,731
CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
The Two-Period Change-Over Design and Its Use in Clinical Trials
Grizzle, J. E. (1965) · Biometrics · doi:10.2307/2528104 · Cited by 784
Correll, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Shapiro, E. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810080052006 · Cited by 355
Contemporary assessment and pharmacotherapy of Tourette syndrome
Scahill, L., Erenberg, G., Berlin, C. M., Budman, C., Coffey, B. J., Jankovic, J., Kiessling, L., King, R. A., Kurlan, R., Lang, A., et al. (2006) · NeuroRX · doi:10.1016/j.nurx.2006.01.009 · Cited by 300
The performance of the two‐stage analysis of two‐treatment, two‐period crossover trials
Freeman, P. R. (1989) · Statistics in Medicine · doi:10.1002/sim.4780081202 · Cited by 272
Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.8.1057 · Cited by 268
Risperidone Versus Pimozide in Tourette's Disorder: A Comparative Double-Blind Parallel-Group Study
Bruggeman, R., van der Linden, C., Buitelaar, J. K., Gericke, G. S., Hawkridge, S. M., & Temlett, J. A. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0111 · Cited by 224
Cited by
the ESSTS Guidelines Group, Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0163-7 · Cited by 461
Nelson, E. A., Walker, S. R., Weisberg, E., Bar-Natan, M., Barrett, R., Gashin, L. B., Terrell, S., Klitgaard, J. L., Santo, L., Addorio, M. R., et al. (2011) · Blood · doi:10.1182/blood-2009-11-255232 · Cited by 280
Ganos, C., & Martino, D. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2014.09.008 · Cited by 119
Metadata
- Authors
- Pringsheim, T., & Marras, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-04-15
- Issue
- 2
- Pages
- CD006996-CD006996
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2142040461
- Cited by
- 258
- References
- 19
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pimozide for tics in Tourette's syndrome. https://app.cochat.ai/papers/10.1002/14651858.cd006996.pub2
- The paper
- Pringsheim, T., & Marras, C. (2009). Pimozide for tics in Tourette's syndrome. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd006996.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.